Bio-Works Technologies AB
STO:BIOWKS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bio-Works Technologies AB
Revenue
Bio-Works Technologies AB
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bio-Works Technologies AB
STO:BIOWKS
|
Revenue
kr43.9m
|
CAGR 3-Years
82%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
O
|
OssDsign AB
STO:OSSD
|
Revenue
kr180.2m
|
CAGR 3-Years
47%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Xvivo Perfusion AB
STO:XVIVO
|
Revenue
kr812.2m
|
CAGR 3-Years
25%
|
CAGR 5-Years
35%
|
CAGR 10-Years
21%
|
|
|
D
|
Doxa AB
STO:DOXA
|
Revenue
kr20.3m
|
CAGR 3-Years
57%
|
CAGR 5-Years
19%
|
CAGR 10-Years
3%
|
|
|
Bactiguard Holding AB
STO:BACTI B
|
Revenue
kr215.9m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
V
|
Vimian Group AB
STO:VIMIAN
|
Revenue
€425m
|
CAGR 3-Years
15%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
Bio-Works Technologies AB
Glance View
Bio-Works Technologies AB engages in the research and development, manufacturing, and supply of agarose-based resins. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2017-12-14. The firm designs, develops, manufactures and supplies products for purification and separation of proteins and other molecules for application in areas such as Research and Laboratory, Life Science and Biopharma, as well as Food and Beverage. The firm uses technology based on uses Agarose beads, which are derived from seaweed in the process of liquid chromatography and serve as adsorbers that bind molecules of interest allowing them to be recovered. Its product offerings, marketed under brand names WorkBeads, BabyBio and OptioBio, include Activated Resin for coupling ligands, BabyBio Columns for rapid protein purification and condition screening, Immobilized Metal-ion Affinity Chromatography (IMAC) Resin, Ion Exchange Chromatography (IEX) Resin and OptioBio Glass Columns for small-scale purification and screening, among others.
See Also
What is Bio-Works Technologies AB's Revenue?
Revenue
43.9m
SEK
Based on the financial report for Dec 31, 2023, Bio-Works Technologies AB's Revenue amounts to 43.9m SEK.
What is Bio-Works Technologies AB's Revenue growth rate?
Revenue CAGR 5Y
46%
Over the last year, the Revenue growth was 6%. The average annual Revenue growth rates for Bio-Works Technologies AB have been 82% over the past three years , 46% over the past five years .
